

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 8, 2021

**LIXTE BIOTECHNOLOGY HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

DELAWARE  
(State or other jurisdiction  
of incorporation)

000-51476  
(Commission  
File Number)

20-2903526  
(I.R.S. Employer  
Identification Number)

161 West Altadena Drive  
Altadena, California 91001  
(Address of principal executive offices)

(631) 830-7092  
(Registrant's telephone number, including area code)

248 Route 25A, No. 2  
East Setauket, New York 11733  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	LIXT	The Nasdaq Stock Market, LLC
Warrants to Purchase Common Stock, par value \$0.0001 per share	LIXTW	The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On July 8, 2021, the Company held its annual meeting of stockholders (the "Annual Meeting"). The matters voted upon were:

**Proposal 1:** The election of six director nominees to the Company's Board of Directors to serve for a one-year term expiring at the 2022 annual meeting of stockholders.

**Proposal 2:** To approve, in an advisory (non-binding) vote, the fiscal year 2020 executive compensation.

**Proposal 3:** To approve, in an advisory (non-binding) vote, the frequency of voting on executive compensation.

**Proposal 4:** To ratify the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.

The results of the voting were as follows:

**Proposal 1 (election of directors):**

Each of the director nominees to the Company's Board of Directors was elected as follows:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Dr. John Kovach	7,627,469	555,142	1,389,252
Dr. Philip Palmedo	7,625,013	557,598	1,389,252
Dr. Stephen Forman	7,627,672	554,939	1,389,252
Dr. Yun Yen	7,624,769	557,842	1,389,252
Gil N Schwartzberg	7,628,019	554,592	1,389,252
Regina Brown	8,176,131	6,480	1,389,252

**Proposal 2 (executive compensation):**

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
8,158,816	21,101	2,694	1,389,252

**Proposal 3 (frequency of vote):**

<b>Frequency/Vote Type</b>	<b>Votes For</b>
3 years	7,566,699
2 years	10,804
1 year	604,137
Abstain	971
Broker Non-Votes	1,389,252

**Proposal 4 (appointment of accounting firm):**

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
8,988,374	581,584	1,905	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 9, 2021

LIXTE BIOTECHNOLOGY HOLDINGS, INC.  
(Registrant)

By: /s/ JOHN S. KOVACH  
John S. Kovach, Chief Executive Officer